Liquidia Gets Bullish Signal from Hikma vs Amarin Ruling
Raymond James reiterates Strong Buy rating and $68 target on Liquidia after the Supreme Court’s positive Hikma v. Amarin decision.
/ 5 items
#UTHR↓
Game-Changer for IPF: Inhaled Tyvaso Preserves Lung Function in Major TETON-1 Study
The United Therapeutics TETON-1 trial shows that inhaled Tyvaso preserves lung function by 130 mL versus placebo and reduces disease progression. Positive results were seen across all patient groups, with an FDA filing planned for this summer.
United Therapeutics’ Once-Daily Pill Cuts Clinical Worsening in PAH by 55%
United Therapeutics' ralinepag reduced clinical worsening risk by 55% in PAH phase 3 study. Once-daily oral drug shows strong efficacy; FDA filing planned for 2026.
United Therapeutics Unveils Tresmi: The "Category Killer" Inhaler Set to End Coughing Woes in PAH and ILD
United Therapeutics announces Tresmi, a revolutionary soft mist inhaler version of Treprostinil that cuts coughing side effects by up to 90%. Planned approval filing this year and launch next year, impacting strategic partner MannKind's stock.
A Breath of Fresh Air: Tyvaso Offers New Hope for Idiopathic Pulmonary Fibrosis
United Therapeutics' Tyvaso Inhalation Solution demonstrates significant benefits in the TETON-2 study for Idiopathic Pulmonary Fibrosis (IPF), offering new hope and potential treatment advancements for this debilitating lung condition.